Lisata Therapeutics, Inc. - Common Stock LSTA 深 沪
已收盘 08-01 16:00:00 美东时间
2.49
+0.010
+0.40%
华盛通- 最 高2.54
- 今 开2.48
- 成交量 2477股
- 最 低 2.46
- 昨 收 2.48
- 总市值 2140.95万
- 52周最高 4.20
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 1.87
- 委 比 81.62%
- 总股本 859.82万
- 历史最高 1483.50
- 量 比 0.14
- 振 幅 3.23%
- 历史最低 1.87
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics announced it will report its second-quarter 2025 financial results on August 7, 2025, followed by a conference call at 4:30 p.m. ET. Interested parties must register via the provided link to receive dial-in details. The call will also be webcast on the company's website and available for replay for 12 months. Lisata focuses on developing therapies for advanced solid tumors, with its candidate certepetide aiming to improve drug...
07-31 12:00
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Lisata Therapeutics and WARPNINE announce the successful completion of patient enrollment in the Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The study, conducted at St John of God Subiaco Hospital, enrolled 30 participants across three treatment cohorts. Updated preliminary data presented at the 2025 ...
07-17 12:00
U.S. Patent And Trademark Office Issues Lisata Therapeutics Composition Of Matter Patent For Certepetide Through March 2040 With Opportunity For Patent Term Extension
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extensionThis patent covers novel cyclic peptides and their use in treating solid tumors
07-15 20:11
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
Lisata Therapeutics获得美国专利商标局颁发的新成分专利，有效期至2040年，涉及创新环状肽certepetide，用于治疗实体瘤。该专利加强了知识产权保护，防止仿制，并为公司未来商业化提供了支持。Certepetide通过激活特定运输系统，提高抗癌药渗入肿瘤的效果，已显示出良好临床疗效。
07-15 12:00
AGITG, NHMRC Clinical Trials Centre At University Of Sydney, And Lisata Therapeutics Announce Preliminary Cohort B Data From ASCEND Phase 2b Trial In Metastatic Pancreatic Cancer
ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentiallyPositive signal in progression-free survival and objective response rate observed in certepetide-treated group
06-26 20:07
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
Preliminary Cohort B data from the ASCEND Phase 2b trial show certepetide improves progression-free survival (PFS), objective response rate (ORR), and safety in metastatic pancreatic cancer patients compared to placebo. Cohort B, with two certepetide doses, showed a 60.8% 6MPFS vs. 25% in placebo, with median PFS of 7.5 vs. 4.7 months. ORR was 45.2% vs. 19%. Final data from both cohorts are expected later this year. Certepetide has a favorable sa...
06-26 12:00
Lisata Therapeutics Advances Certepetide for Cancer Treatment
The latest announcement is out from Lisata Therapeutics ( ($LSTA) ). Lisata The...
06-17 21:27
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
<p>Lisata Therapeutics and GATC Health Corp. have formed a strategic alliance to accelerate drug development using GATC’s AI-powered Multiomics Advanced Technology (MAT) platform. Lisata will leverage GATC’s MAT platform to identify new combination therapies, including their certepetide drug candidate, across all therapeutic areas. The collaboration aims to enhance the success rate of drug development by predicting safety, efficacy, and side effe...
06-17 12:00
Lisata Therapeutics Amends Executive Employment Agreements
The latest update is out from Lisata Therapeutics ( ($LSTA) ). On June 10, 2025...
06-14 04:49
Lisata Therapeutics to Present at the 2025 BIO International Convention
Lisata Therapeutics' CEO, Dr. David J. Mazzo, will present at the 2025 BIO International Convention in Boston on June 17. The company focuses on developing innovative therapies for advanced solid tumors using its CendR Platform, which powers its lead candidate, certepetide. Lisata expects to announce key milestones over the next 1.5 years and anticipates funding into Q3 2026.
06-11 12:30
